Search | OpenScholar

Search results

1934 results found

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism Relat Disord 2019;64:175-180.

Publication: Journal Article

Hauser, RA, SH Isaacson, A Ellenbogen, BE Safirstein, DD Truong, SF Komjathy, DM Kegler-Ebo, P Zhao, and C Oh. 2019. “Orally Inhaled Levodopa (CVT-301) for Early Morning OFF Periods in Parkinson’s Disease. Parkinsonism Relat Disord 2019;64:175-180.”. Parkinsonism Relat Disord.

Prevalence of Dyskinesia and OFF by 30-minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.

Publication: Journal Article

Hauser, RA, DE Kremens, LW Elmer, DL Kreitzman, RR Walsh, R Johnson, R Howard, JT Nguyen, and R Patni. 2019. “Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.”. J Parkinsons Dis.

Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol 2019;86:153-157.

Publication: Journal Article

Vollstedt, EJ, M Kasten, C Klein, and MJFF Global Genetic Parkinson’s Disease Study Group. 2019. “Using Global Team Science to Identify Genetic Parkinson’s Disease Worldwide. Ann Neurol 2019;86:153-157.”. Ann Neurol.

Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.

Publication: Journal Article

Hermanowicz, N, SA Jones, and RA Hauser. 2019. “Impact of Non-Motor Symptoms in Parkinson’s Disease: A PMDAlliance Survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.”. Neuropsychiatry Dis Treat.

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018;389:10-16.

Publication: Journal Article

“Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The Nosology of Tardive Syndromes. J Neurol Sci 2018;389:10-16.”. 2018. J Neurol Sci.

Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci 2017;373:116-123.

Publication: Journal Article

Tetrud, J, P Nausieda, D Kreitzman, GS Liang, A Nieves, AP Duker, RA Hauser, et al. 2017. “Conversion to Carbidopa and Levodopa Extended-Release (IPX066) Followed by Its Extended Use in Patients Previously Taking Controlled-Release Carbidopa-Levodopa for Advanced Parkinson’s Disease. J Neurol Sci 2017;373:116-123.”. J Neurol Sci .

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.

Publication: Journal Article

Hauser, RA, SA Factor, SR Marder, MA Knesevich, PM Ramirez, , J Burke, GS Liang, and CF O’Brien. 2017. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.”. Am J Psychiatry.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Mov Disord 2017;32:783-789.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Leinonen, N Giladi, RA Hauser, OS Klepiskaya, DL Kreitzman, et al. 2017. “A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease. Mov Disord 2017;32:783-789.”. Mov Disord.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology 2017;88:2003-2010.

Publication: Journal Article

Fernandez, HH, SA Factor, RA Hauser, J Jimenez-Shahed, and . 2017. “Randomized Controlled Trial of Deutetrabenazine for Tardive Dyskinesia: The ARM-TD Study. Neurology 2017;88:2003-2010.”. Neurology.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017;32:1701-1709.

Publication: Journal Article

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.